Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00336154
Status:
WITHDRAWN
Last Update Posted:
2020-10-28
First Post:
2006-06-12
Brief Title:
Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
Sponsor:
Rambam Health Care Campus
Organization:
Rambam Health Care Campus
Study Overview
Official Title:
Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa
Status:
WITHDRAWN
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Epidermolysis BullosaEB is an inherited bullous disease Tetracycline is believed to have anti inflammatory properties 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo After one month of wash out they will be treated for additional 4 m with placebo or tetracycline The patients will be examined each month to estimate bulla formationrate of healing
Detailed Description:
Epidermolysis BullosaEB is an inherited bullous disease Tetracycline is believed to have anti inflammatory properties 20 patients with EB older than 13 years will be treated for 4 months with tetracycline or placebo After one month of wash out they will be treated for additional 4 m with placebo or tetracycline The patients will be examined each month to estimate bulla formationrate of healing
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None